Kyowa Kirin Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kyowa Kirin Co., Ltd.
Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
- Archimedes Pharma Ltd.
- Centus Biotherapeutics Ltd.
- Daiichi Fine Chemical Co., Ltd.
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
- Kirin Pharma Company, Limited
- Kyowa Kirin Asia Pacific Pte. Ltd.
- Kyowa Kirin Australia Pty Ltd
- Kyowa Kirin International PLC
- Kyowa Pharma Chemical Co., Ltd.
- ProStrakan Group plc
- Kyowa Kirin
- Kyowa Kirin Frontier Co., Ltd.
- Kyowa Hakko Kirin (Singapore) Pte. Ltd.
- Kyowa Hakko Kirin Co., Ltd.